Edition:
India

Lupin Ltd (LUPN.BO)

LUPN.BO on Bombay Stock Exchange

1,060.85INR
23 Jun 2017
Change (% chg)

Rs-6.10 (-0.57%)
Prev Close
Rs1,066.95
Open
Rs1,064.00
Day's High
Rs1,085.00
Day's Low
Rs1,058.80
Volume
97,904
Avg. Vol
104,237
52-wk High
Rs1,750.00
52-wk Low
Rs1,058.80

LUPN.BO

Chart for LUPN.BO

About

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central... (more)

Overall

Beta: -0.08
Market Cap(Mil.): Rs478,827.31
Shares Outstanding(Mil.): 451.72
Dividend: 7.50
Yield (%): 0.71

Financials

  LUPN.BO Industry Sector
P/E (TTM): 18.77 13.63 17.39
EPS (TTM): 56.46 -- --
ROI: 13.46 -6.95 -5.22
ROE: 20.74 -6.42 -4.48

BRIEF-Lupin launches generic Topicort LP Emollient and Topicort cream in U.S.

* Says Lupin launches generic Topicort LP Emollient cream and Topicort cream in the U.S.

22 Jun 2017

BUZZ-India's Lupin hits near 3-yr low, technicals suggest further downside

** Shares of Lupin Ltd fall as much as 2.3 pct to 1,070.1 rupees, their lowest since July 2014

22 Jun 2017

BRIEF-Lupin launches generic Wellbutrin XL tablets in the U.S.

* Says launches generic Wellbutrin XL tablets in the U.S. Source text: (http://bit.ly/2tpruCi) Further company coverage:

15 Jun 2017

BRIEF-Lupin receives U.S. FDA approval for generic Roxicodone tablets

* Says Lupin receives FDA approval for generic Roxicodone tablets

14 Jun 2017

BUZZ-India's Lupin slumps to near 3-yr low on weak qtrly results

** Lupin Ltd falls as much as 7.7 pct to its lowest since Aug. 8, 2014

25 May 2017

Lupin warns of more pricing pressure as fourth-quarter profit halves

MUMBAI Indian drugmaker Lupin Ltd expects to launch over 30 products in the United States this year, but warned revenue growth would remain muted due to growing pricing pressure and competition in the world's largest healthcare market.

24 May 2017

UPDATE 2-Indian drugmaker Lupin warns of more pricing pressure as Q4 profit halves

* Q4 net profit 3.80 bln rupees vs est. 6.45 bln rupees (Adds comments from interview with managing director)

24 May 2017

BRIEF-Lupin MD Nilesh Gupta says co expects to launch more than 30 products in U.S. in FY18

* MD Nilesh Gupta says expects to launch more than 30 products in US in FY18

24 May 2017

India's Lupin Q4 net profit halves

MUMBAI, May 24 Lupin Ltd, India's second-largest drugmaker by sales, reported that its quarterly net profit nearly halved from a year ago, coming in well below analysts' expectations as sales slumped in its largest market the United States.

24 May 2017

BRIEF-India's Lupin March-qtr consol profit down about 49 pct

* Consensus forecast for March quarter consol profit was 6.45 billion rupees

24 May 2017

More From Around the Web

Earnings vs. Estimates